The selective VEGFR inhibitor PTK787/ZK 222584 represses the activities of VEGFR-negative bone marrow-derived mesenchymal stem cells

Cancer Biol Ther. 2009 Jul;8(13):1249-51. doi: 10.4161/cbt.8.13.8996. Epub 2009 Jul 13.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Apoptosis / drug effects
  • Blotting, Western
  • Bone Marrow Cells / cytology
  • Bone Marrow Cells / drug effects
  • Bone Marrow Cells / metabolism
  • Cell Differentiation / drug effects
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects*
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Gene Expression Profiling
  • Humans
  • Mesenchymal Stem Cells / cytology
  • Mesenchymal Stem Cells / drug effects*
  • Mesenchymal Stem Cells / metabolism
  • Models, Biological
  • Phthalazines / pharmacology*
  • Protein Kinase Inhibitors / pharmacology
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Protein-Tyrosine Kinases / genetics
  • Protein-Tyrosine Kinases / metabolism*
  • Pyridines / pharmacology*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Vascular Endothelial Growth Factor Receptor-1 / antagonists & inhibitors
  • Vascular Endothelial Growth Factor Receptor-1 / genetics
  • Vascular Endothelial Growth Factor Receptor-1 / metabolism

Substances

  • Phthalazines
  • Protein Kinase Inhibitors
  • Pyridines
  • vatalanib
  • Protein-Tyrosine Kinases
  • Vascular Endothelial Growth Factor Receptor-1